CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 157-168 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Real-World Efficacy and Safety of Standard-of-Care Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM).

Theprungsirikul P; Wang R; Chang SH; Bar N; Browning S; Parker T; Wang SY; Neparidze N

Jan 1, 2026European journal of haematology

2026PubMedDirectly related

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

Sujjitjoon J; Kongkla K; Yuti P; Sawasdee N; Natungnuy K; Poungvarin N; Yenchitsomanus PT

Jan 1, 2026Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2026PubMedDirectly related

Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus.

Wen W; Li X; Liu T; Zhang SM; Sun D; Zhao XD; Cheng CY; Zhang LM; Zhang JP; Zhang XB

Jan 1, 2026Cytotherapy

2026PubMedDirectly related

Integrating AI, RNA Vaccines, and CAR-T Cells for Personalized Treatment.

Haykal D; Dréno B

Jan 1, 2026Journal of immunology research

2026PubMedSupporting evidence

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

Kawamoto H; Kawase T; Nagano S

Jan 1, 2026[Rinsho ketsueki] The Japanese journal of clinical hematology

2026PubMedDirectly related

A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors.

Panikkanvalappil SR; Maloney E; Ahn SW; Martin S; Marlin C; Bhagavatula SK; Jonas O

Jan 1, 2026Science advances

2026PubMedDirectly related

[Development of memory-like CAR-NK cells with durable antitumor activity].

Nakashima T; Kagoya Y

Jan 1, 2026[Rinsho ketsueki] The Japanese journal of clinical hematology

2026PubMedDirectly related

Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.

Maccagno M; Tagliero R; Chiarle R; Voena C

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Advanced therapy medicinal products in Saudi Arabia: Regulation and development.

AlMuhanna MH; Alharbi M; Aldahash A; Felemban R; Asiri L; Alghamdi M; Alzahrani R; Aldossary W; Alenzi N; Almohaywi M

Jan 1, 2026Regenerative therapy

2026PubMedDirectly related

The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.

Boutier H; Feldmann A; Bachmann M

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.

Chen A; Pulido JS; Tonne J; Metko M; Thompson JM; Sangsuwannukul T; Chiriboga-Yerovi MP; Diaz RM; Webb MJ; Huff AL; Moore M; Schuelke MR; Irshad S; Appleton E; Melcher A; Kendall B; Vile RG

Jan 1, 2026Cancer immunology research

2026PubMedDirectly related

The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.

Smail SW; Hamza HT; Ali MA; Yashooa RK; Nooh WA; Bapir AA; Rahman DB; Rahman MO; Haseeb HA; Maaruf NB; Majeed SO; Ezzat I; Janson C

Jan 1, 2026Pharmaceutics